Concurrent Nonavalent Human Papillomavirus (HPV) Vaccination and Immune Stimulation with Imiquimod to Treat Recalcitrant HPV-associated High Grade Vaginal Intra-epithelial Neoplasia

Overview

Journal Gynecol Oncol Rep

Publisher Elsevier

Date 2024 Mar 6

PMID 38445009

Authors

R Farrell

J Zaunders

I M Poynten

L Anderson

L Evans

Affiliations

Soon will be listed here.

Abstract

This is the first report describing detailed T cell responses to viral-like proteins contained in an HPV specific vaccine given in combination with Imiquimod for treatment of persistent VAIN2/3. We postulate that stimulation of the innate immune system with Imiquimod and the specific CD4 and CD8T cell responses following HPV vaccination with Gardasil9 combined to induce clinical remission in a woman with treatment-refractory disease.

References

Dodge J, Eltabbakh G, Mount S, Walker R, Morgan A . Clinical features and risk of recurrence among patients with vaginal intraepithelial neoplasia. Gynecol Oncol. 2001; 83(2):363-9. DOI: 10.1006/gyno.2001.6401. View

Dehlendorff C, Baandrup L, Kjaer S . Real-World Effectiveness of Human Papillomavirus Vaccination Against Vulvovaginal High-Grade Precancerous Lesions and Cancers. J Natl Cancer Inst. 2020; 113(7):869-874. PMC: 8246827. DOI: 10.1093/jnci/djaa209. View

Lichter K, Krause D, Xu J, Tsai S, Hage C, Weston E . Adjuvant Human Papillomavirus Vaccine to Reduce Recurrent Cervical Dysplasia in Unvaccinated Women: A Systematic Review and Meta-analysis. Obstet Gynecol. 2020; 135(5):1070-1083. DOI: 10.1097/AOG.0000000000003833. View

Lei J, Ploner A, Elfstrom K, Wang J, Roth A, Fang F . HPV Vaccination and the Risk of Invasive Cervical Cancer. N Engl J Med. 2020; 383(14):1340-1348. DOI: 10.1056/NEJMoa1917338. View

Inayama Y, Yamanishi Y, Nakatani E, Aratake J, Sasagasako N, Yamada K . Imiquimod for vaginal intraepithelial neoplasia 2-3: A systematic review and meta-analysis. Gynecol Oncol. 2020; 160(1):140-147. DOI: 10.1016/j.ygyno.2020.09.031. View

Juno J, van Bockel D, Kent S, Kelleher A, Zaunders J, Munier C . Cytotoxic CD4 T Cells-Friend or Foe during Viral Infection?. Front Immunol. 2017; 8:19. PMC: 5253382. DOI: 10.3389/fimmu.2017.00019. View

Shibata T, Shah S, Evans T, Coleman H, Lieblong B, Spencer H . Expansion of Human Papillomavirus-Specific T Cells in Periphery and Cervix in a Therapeutic Vaccine Recipient Whose Cervical High-Grade Squamous Intraepithelial Lesion Regressed. Front Immunol. 2021; 12:645299. PMC: 8515132. DOI: 10.3389/fimmu.2021.645299. View

Sopracordevole F, Barbero M, Clemente N, Fallani M, Cattani P, Agarossi A . High-grade vaginal intraepithelial neoplasia and risk of progression to vaginal cancer: a multicentre study of the Italian Society of Colposcopy and Cervico-Vaginal Pathology (SICPCV). Eur Rev Med Pharmacol Sci. 2016; 20(5):818-24. View

Kechagias K, Kalliala I, Bowden S, Athanasiou A, Paraskevaidi M, Paraskevaidis E . Role of human papillomavirus (HPV) vaccination on HPV infection and recurrence of HPV related disease after local surgical treatment: systematic review and meta-analysis. BMJ. 2022; 378:e070135. PMC: 9347010. DOI: 10.1136/bmj-2022-070135. View

10.

Kesic V, Carcopino X, Preti M, Vieira-Baptista P, Bevilacqua F, Bornstein J . The European Society of Gynaecological Oncology (ESGO), the International Society for the Study of Vulvovaginal Disease (ISSVD), the European College for the Study of Vulval Disease (ECSVD), and the European Federation for Colposcopy (EFC) consensus.... Int J Gynecol Cancer. 2023; 33(4):446-461. PMC: 10086489. DOI: 10.1136/ijgc-2022-004213. View

11.

Hodeib M, Cohen J, Mehta S, Rimel B, Walsh C, Li A . Recurrence and risk of progression to lower genital tract malignancy in women with high grade VAIN. Gynecol Oncol. 2016; 141(3):507-510. DOI: 10.1016/j.ygyno.2016.03.033. View

12.

Tainio K, Jakobsson M, Louvanto K, Kalliala I, Paavonen J, Nieminen P . Randomised trial on treatment of vaginal intraepithelial neoplasia-Imiquimod, laser vaporisation and expectant management. Int J Cancer. 2016; 139(10):2353-8. DOI: 10.1002/ijc.30275. View

13.

Serrano B, de Sanjose S, Tous S, Quiros B, Munoz N, Bosch X . Human papillomavirus genotype attribution for HPVs 6, 11, 16, 18, 31, 33, 45, 52 and 58 in female anogenital lesions. Eur J Cancer. 2015; 51(13):1732-41. DOI: 10.1016/j.ejca.2015.06.001. View

14.

van Poelgeest M, Welters M, Vermeij R, Stynenbosch L, Loof N, Berends-van der Meer D . Vaccination against Oncoproteins of HPV16 for Noninvasive Vulvar/Vaginal Lesions: Lesion Clearance Is Related to the Strength of the T-Cell Response. Clin Cancer Res. 2016; 22(10):2342-50. DOI: 10.1158/1078-0432.CCR-15-2594. View

15.

Bryan S, Barbara C, Thomas J, Olaitan A . HPV vaccine in the treatment of usual type vulval and vaginal intraepithelial neoplasia: a systematic review. BMC Womens Health. 2019; 19(1):3. PMC: 6323700. DOI: 10.1186/s12905-018-0707-9. View